<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8704895</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5536</journal-id>
<journal-id journal-id-type="nlm-ta">Leukemia</journal-id>
<journal-id journal-id-type="iso-abbrev">Leukemia</journal-id>
<journal-title-group>
<journal-title>Leukemia</journal-title>
</journal-title-group>
<issn pub-type="ppub">0887-6924</issn>
<issn pub-type="epub">1476-5551</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29930300</article-id>
<article-id pub-id-type="pmc">6169730</article-id>
<article-id pub-id-type="doi">10.1038/s41375-018-0176-z</article-id>
<article-id pub-id-type="manuscript">EMS77878</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2
translation in T-ALL</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kampen</surname>
<given-names>Kim R.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sulima</surname>
<given-names>Sergey O.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Verbelen</surname>
<given-names>Benno</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Girardi</surname>
<given-names>Tiziana</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vereecke</surname>
<given-names>Stijn</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rinaldi</surname>
<given-names>Gianmarco</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Verbeeck</surname>
<given-names>Jelle</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de Beeck</surname>
<given-names>Joyce Op</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Uyttebroeck</surname>
<given-names>Anne</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Meijerink</surname>
<given-names>Jules P. P.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Moorman</surname>
<given-names>Anthony V.</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Harrison</surname>
<given-names>Christine J.</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Spincemaille</surname>
<given-names>Pieter</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cools</surname>
<given-names>Jan</given-names>
</name>
<xref ref-type="aff" rid="A8">8</xref>
<xref ref-type="aff" rid="A9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cassiman</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fendt</surname>
<given-names>Sarah-Maria</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vermeersch</surname>
<given-names>Pieter</given-names>
</name>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>De Keersmaecker</surname>
<given-names>Kim</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Laboratory for Disease Mechanisms in Cancer, Department of
Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium</aff>
<aff id="A2"><label>2</label>Laboratory of Cellular Metabolism and Metabolic Regulation,
Center for Cancer Biology, VIB, Leuven, Belgium</aff>
<aff id="A3"><label>3</label>Laboratory of Cellular Metabolism and Metabolic Regulation,
Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven,
Belgium</aff>
<aff id="A4"><label>4</label>Department of Pediatric Oncology &amp; Hematology,
University Hospitals Leuven, Leuven, Belgium</aff>
<aff id="A5"><label>5</label>Princess Máxima Center for Pediatric Oncology,
Utrecht, The Netherlands</aff>
<aff id="A6"><label>6</label>Leukaemia Research Cytogenetics Group, Northern Institute
for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom</aff>
<aff id="A7"><label>7</label>Department of Gastroenterology-Hepatology and Metabolic
Center, University Hospitals Leuven, Leuven, Belgium</aff>
<aff id="A8"><label>8</label>Laboratory of Molecular Biology of Leukemia, Center for
Human Genetics, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium</aff>
<aff id="A9"><label>9</label>Laboratory of Molecular Biology of Leukemia, Center for
Cancer Biology, VIB, Leuven, Belgium</aff>
<aff id="A10"><label>10</label>Department of Laboratory Medicine, University Hospitals
Leuven, Leuven, Belgium</aff>
<author-notes>
<corresp id="CR1">Corresponding author: Prof. Kim De Keersmaecker, Laboratory for
Disease Mechanisms in Cancer, Department of Oncology, KU Leuven and Leuven
Cancer Institute (LKI), Campus Gasthuisberg O&amp;N1, Herestraat 49 box 603,
3000 Leuven, Belgium, <email>kim.dekeersmaecker@kuleuven.be</email>, phone : +32
16 37 31 67.</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>23</day>
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>21</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>2</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>27</day>
<month>2</month>
<year>2019</year>
</pub-date>
<volume>33</volume>
<issue>2</issue>
<fpage>319</fpage>
<lpage>332</lpage>
<!--elocation-id from pubmed: 10.1038/s41375-018-0176-z-->
<permissions>
<license>
<license-p>Users may view, print, copy, and download text and data-mine the
content in such documents, for the purposes of academic research, subject
always to the full Conditions of use:<ext-link ext-link-type="uri" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</ext-link></license-p>
</license>
</permissions>
<abstract>
<p id="P1">The R98S mutation in ribosomal protein L10 (RPL10 R98S) affects 8% of
pediatric T-cell acute lymphoblastic leukemia (T-ALL) cases, and was previously
described to impair cellular proliferation. The current study reveals that RPL10
R98S cells accumulate reactive oxygen species which promotes mitochondrial
dysfunction and reduced ATP levels, causing the proliferation defect. RPL10 R98S
mutant leukemia cells can overcome high oxidative stress levels via a specific
increase of IRES-mediated translation of the anti-apoptotic factor B-cell
lymphoma 2 (BCL-2), mediating BCL-2 protein overexpression. RPL10 R98S selective
sensitivity to the clinically available Bcl-2 inhibitor Venetoclax (ABT-199) was
supported by suppression of splenomegaly and the absence of human leukemia cells
in the blood of T-ALL xenografted mice. These results shed new light on the
oncogenic function of ribosomal mutations in cancer, provide a novel mechanism
for BCL-2 upregulation in leukemia, and highlight BCL-2 inhibition as a novel
therapeutic opportunity in RPL10 R98S defective T-ALL.</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P2">T-cell acute lymphoblastic leukemia (T-ALL) is a genetically complex and
aggressive hematologic cancer caused by the accumulation of somatic mutations in
developing T-cells.<xref ref-type="bibr" rid="R1">1</xref> Outcomes of T-ALL
improved with the advent of high-dose, multi-agent chemotherapy regimens, resulting
in long-term event free survival (EFS) rates above 80% in pediatric patients.<xref ref-type="bibr" rid="R2">2</xref> However, relapses due to therapy resistance or
initial therapy failure remain a problem and are the most common causes of death. To
further improve therapy, targeted treatments are necessary that specifically
interfere with the cellular processes deregulated in genetic subgroups of pediatric
T-ALL patients.</p>
<p id="P3">Ribosomes are the cellular components that execute protein translation of
mRNAs. Mutations in 4 different ribosomal proteins (RPL5, RPL10, RPL22 and RPL11)
have been described in T-ALL, with the highest incidence of genetic lesions
occurring at residue R98 of ribosomal protein L10 (RPL10).<xref ref-type="bibr" rid="R3">3</xref>–<xref ref-type="bibr" rid="R5">5</xref> The RPL10 R98S
missense mutational hotspot was identified in 8% of pediatric T-ALL cases.<xref ref-type="bibr" rid="R4">4</xref> The R98 residue is located at the base of an
essential flexible loop near the ribosomal catalytic core in the 60S subunit. This
loop is required for proper 60S assembly and translational fidelity, and we have
previously demonstrated that mutant RPL10 R98S yeast and mouse lymphoid cells
display impaired ribosome formation and proliferation.<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R6">6</xref> Besides its function in
regulating translation-associated functions, RPL10 has a known extra-ribosomal
function of binding the transcription factor AP-1 (proto-oncogene c-Jun), thereby
interfering with c-Jun transcriptional activation.<xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R8">8</xref> Additionally, RPL10 has been
proposed to inhibit the activity of the Src family kinase Yes.<xref ref-type="bibr" rid="R9">9</xref> Moreover, a study investigating the RPL10 H213Q mutation
associated with autism spectrum disorder indicates a function for RPL10 in cell
metabolism.<xref ref-type="bibr" rid="R10">10</xref> In the context of T-ALL, we
recently found RPL10 R98S mutations to be mutually exclusive with JAK/STAT
mutations.<xref ref-type="bibr" rid="R11">11</xref> While existing literature on
RPL10 points to several promising candidates for therapeutic intervention, no
therapeutic strategy has been validated in a mouse model so far. Moreover, while the
observed hypoproliferation phenotype associated with the RPL10 R98S mutation has
been tied to ribosome assembly defects in yeast, no causal mechanisms for this
proliferation phenotype have been elucidated in mammalian cells yet.</p>
<p id="P4">In the present study, we describe the RPL10 R98S ribosomal mutation
associated phenotypes, and that hypoproliferation of RPL10 R98S cells is influenced
by mitochondrial dysfunction. A leukemic cell survival benefit is facilitated by the
R98S mutant ribosome specific IRES-mediated BCL-2 translation. Finally, we
demonstrate that the RPL10 R98S specific elevated BCL-2 expression sensitizes RPL10
R98S leukemia to the clinical inhibitor ABT-199, and that ABT-199 suppresses
leukemia progression <italic>in vivo</italic>.</p>
</sec>
<sec id="S2" sec-type="methods">
<title>Methods</title>
<sec id="S3">
<title>Cell cultures</title>
<p id="P5">Ba/F3 and Jurkat cells (DSMZ) were cultured in RPMI-1640 (Life
technologies) with 10-20% Fetal Bovine Serum (FBS) (Thermo Fisher Scientific).
Mouse lymphoid-B-cell Ba/F3 RPL10 WT and RPL10 R98S mutant clones were generated
as previously described.<xref ref-type="bibr" rid="R11">11</xref> CRISPR/Cas9
genome editing was used to introduce the RPL10 R98S point mutation in the Jurkat
T-ALL cell line as described in the <xref ref-type="supplementary-material" rid="SD1">supplementary data file</xref>.</p>
</sec>
<sec id="S4">
<title>MTS assay</title>
<p id="P6">Cell proliferation was assessed using the CellTiter 96 Aqueous One
Solution Cell Proliferation assay (MTS) (Promega). Cells were plated at a
density of 0.25 * 10<sup>6</sup> in the presence or absence of
Nac/H<sub>2</sub>O<sub>2</sub> for 48h.</p>
</sec>
<sec id="S5">
<title>Generation of a conditional Rpl10 R98S knock in mouse line
(<italic>Rpl10<sup>cKI R98S</sup></italic>)</title>
<p id="P7">Generation of this mouse model was performed by the company Polygene AG
(Rümlang, Switzerland) and was previously described.<xref ref-type="bibr" rid="R11">11</xref></p>
</sec>
<sec id="S6">
<title>Serial re-plating assay</title>
<p id="P8"><italic>Rpl10<sup>cKI R98S</sup></italic> mice were crossed with Mx1-Cre
mice (<xref ref-type="supplementary-material" rid="SD1">Figure S1A</xref>).
Lineage negative cells were isolated (EasySep Mouse Hematopoietic Progenitor
Cell enrichment kit, Stemcell Technologies) from 6-8 weeks old male Mx1-Cre
Rpl10<sup>cKI R98S</sup> mice and from Mx1-Cre control mice. Cells were
plated at 2000 cells/ml in Methocult (M3534, Stemcell Technologies) containing
1250 units/ml of interferonβ for complete recombination (IFNβ)
(R&amp;D systems) (<xref ref-type="supplementary-material" rid="SD1">Figure
S1B</xref>). More details are in the data supplement.</p>
</sec>
<sec id="S7">
<title>T-ALL patient samples</title>
<p id="P9">This study was approved by the ethics committees at the institutes
involved. After getting written informed consent, the mononuclear cell fraction
of BM from pediatric T-ALL patients was obtained (<xref ref-type="supplementary-material" rid="SD1">Table S4</xref>).</p>
</sec>
<sec id="S8">
<title>Proteomics</title>
<p id="P10">Cells from 3 monoclonal Ba/F3 cultures expressing WT or R98S RPL10 were
lysed in lysis buffer (Cell Signaling Technology) with addition of 5mM
Na<sub>3</sub>VO<sub>4</sub> and protease inhibitors (Complete, Roche).
Twenty µg of protein were processed for quantitative proteomics as
previously described.<xref ref-type="bibr" rid="R11">11</xref> Data are
available via ProteomeXchange with identifier PXD005995.<xref ref-type="bibr" rid="R11">11</xref></p>
</sec>
<sec id="S9">
<title>Immunoblotting</title>
<p id="P11">1*10<sup>6</sup> cells were lysed (cell lysis buffer, Cell signaling
technology) and denatured in 1x Laemmli sample buffer (Bio-rad) containing
2-mercaptoethanol (Sigma Aldrich). Proteins were separated on Criterion
Tris-Glycine eXtended gels (Bio-rad), transferred to PVDF membranes using the
Trans-Blot Turbo system (Bio-rad), incubated with primary antibodies targeting
Catalase (Cell Signaling #14097 &amp; Abcam #ab76024), xanthine oxidase
(Abcam #ab109235), Bcl-2 (Cell Signaling #2870), and with secondary antibody
Goat Anti-Rabbit or Goat Anti-Mouse IgG-HRP (Thermo Fischer). Proteins were
visualized using chemiluminescence on an Azure C600 (Azure Biosystems).
Quantification was performed using LI-COR Image Studio Lite software version
5.2. Vinculin (Sigma Aldrich), tubulin or beta actin (Sigma Aldrich) was used to
normalize for protein input.</p>
</sec>
<sec id="S10">
<title><sup>13</sup>C Tracer analysis</title>
<p id="P12">Labeling experiments were performed in dialyzed serum for 48 h.
<sup>13</sup>C<sub>6</sub>-glucose tracer was purchased from Sigma-Aldrich.
The cell quenching procedures and the metabolite preparations were described
before.<xref ref-type="bibr" rid="R12">12</xref> Metabolites were
derivatized and measured as described before.<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R14">14</xref> Mass distribution
vectors were extracted from the raw ion chromatograms using a custom Matlab
M-file, which applies consistent integration bounds and baseline correction to
each ion. Data is corrected for naturally occurring isotopes. More details are
in the data supplement.</p>
</sec>
<sec id="S11">
<title>Flow cytometry</title>
<p id="P13">Cells were stained for 30 mins with 5nM dihydroethidium (Life
technologies) for the detection of reactive oxygen species, with 400nM
mitotracker (Cell signaling technology) to detect active mitochondria, or with
4uL human or mouse CD45 antibody (ebioscience #17-9459-42, BD biosciences
#557659). The cells were analyzed using a MACSQuant VYB (Miltenyi) flow
cytometer and FlowJo software. Viable cell counts/mL were determined by FSC/SSC
performed with and without administration of hydrogen peroxide
(H<sub>2</sub>O<sub>2</sub>, 20uM, Sigma Aldrich) or N-acetyl-cysteine (NAC,
1-5mM, Sigma Aldrich). Annexin V-RPE (IQ products), Propidium iodide (PI, Sigma
Aldrich) and active caspase 3 (BD biosciences) were used as apoptotic markers in
the experiments with doxorubicin, maritoclax (Selleckchem) and/or ABT-199 (LC
Laboratories).</p>
</sec>
<sec id="S12">
<title>Ribosomal fractionation and qRT-PCR</title>
<p id="P14">Cell lysates from three Ba/F3 RPL10 WT and three R98S clones were
applied on a sucrose gradient and centrifuged in order to get a distribution of
monosomes and polysomes as described before.<xref ref-type="bibr" rid="R11">11</xref> Seven fractions of equal volume were collected (<xref ref-type="supplementary-material" rid="SD1">Figure S7B</xref>). For
technical reasons, the three fractions corresponding to the highest polysomes
were subsequently combined and considered as 1 fraction. RNA was extracted from
equal volumes of the 5 remaining fractions followed by cDNA synthesis. On each
fraction, qRT-PCR was performed for <italic>Bcl-2</italic> and
<italic>Hprt</italic> in quadruplicate. Primer sequences: mouse
<italic>Bcl-2</italic> forward ATC GCC CTG TGG ATG ACT GAG, reverse CAG CCA
GGA GAA ATC AAA CAG AGG, and mouse <italic>Hprt</italic> forward CAT TAT GCC GAG
GAT TTG G, reverse GCA AGT CTT TCA GTC CTG T.</p>
</sec>
<sec id="S13">
<title>Xenografts in NOD.Cg-Prkdc<sup>scid</sup> Il2rg<sup>tm1Wjl</sup>/SzJ (NSG)
mice</title>
<p id="P15">NSG animal experiments were approved by the local ethics committee
(P179/2015). Human T-ALL patient samples were engrafted by tail vein injections
of 10<sup>6</sup> cells. Blood samples were obtained every two weeks from the
facial vein. Animals reaching &gt;90% human CD45 expressing cells in their
peripheral blood were sacrificed. Terminal cardiac bleeding was performed under
pentobarbital (150mg/kg) anesthesia to obtain blood plasma.</p>
</sec>
<sec id="S14">
<title>BCL-2 IRES reporter assay</title>
<p id="P16">The BCL-2 IRES plasmids were a kind gift from Dr. Adi Kimchi (Weizmann
institute of science).<xref ref-type="bibr" rid="R15">15</xref> IRES activities
were tested in CRISPR-Cas9 engineered RPL10 WT and RPL10 R98S Jurkat cells using
dual luciferase reporter assays (Promega) as detailed in the <xref ref-type="supplementary-material" rid="SD1">supplementary
section</xref>.</p>
</sec>
<sec id="S15">
<title>Statistics</title>
<p id="P17">Statistical analyses were performed using IBM SPSS 23 (IBM Analytics)
software. A two-tailed student’s t-test was used to compare RPL10 WT and
RPL10 R98S mutational groups for all <italic>in vitro</italic> and <italic>in
vivo</italic> measurements based upon Levene's Test for Equality of
Variances. When data of multiple independent mouse experiments were combined, we
made use of the Mann-Whitney U test due to unequal distribution of the data as
mentioned in the text where applicable. The statistical tests used are indicated
for each experiment that has been performed.</p>
</sec>
</sec>
<sec id="S16" sec-type="results">
<title>Results</title>
<sec id="S17">
<title>Proteomic profiling of RPL10 R98S cells identifies an increase in peroxisomal
β-oxidation</title>
<p id="P18">We previously described that RPL10 R98S impairs proliferation of
lymphoid Ba/F3 cells under exponential growth conditions.<xref ref-type="bibr" rid="R4">4</xref> Moreover, in a recent study we described a quantitative
proteomics mass spectrometry analysis of these RPL10 WT and R98S Ba/F3
clones.<xref ref-type="bibr" rid="R11">11</xref> Yet, the underlying
mechanism of hypoproliferation as a cellular phenotype of the RPL10 R98S
mutation remains unknown. To gain insights into the causes of hypoproliferation,
we explored KEGG pathway analysis of the proteomics dataset. The peroxisome and
associated metabolic pathways were upregulated in the Rpl10 R98S Ba/F3 cells
(<xref ref-type="fig" rid="F1">Figure 1A/B</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S1/2</xref>, FDR &lt;
0.1). For two of these genes, elevated mRNA expression levels were detected
(<xref ref-type="supplementary-material" rid="SD1">Figure S1</xref>).
Peroxisomes are membrane-enclosed cellular organelles in which
β-oxidation of very long-chain fatty acids occurs. During peroxisomal
β-oxidation high levels of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)
are produced, which form a selective substrate for the anti-oxidant catalase
(<xref ref-type="fig" rid="F1">Figure 1B</xref>), a marker for peroxisome
activity.<xref ref-type="bibr" rid="R16">16</xref> In accordance with higher
protein expression of peroxisome enzymes, catalase protein expression was
significantly elevated in Rpl10 R98S Ba/F3 cells (<xref ref-type="supplementary-material" rid="SD1">Figure S3A</xref>,
student’s t-test, p = 0.045), in lineage negative (lin-) bone marrow (BM)
cells extracted from MX1-Cre Rpl10 R98S mutant knock-in mice
(<italic>Rpl10<sup>cKI R98S</sup></italic>) (<xref ref-type="supplementary-material" rid="SD1">Figure S2A/B and S3B</xref>,
student’s t-test, p = 0.003), and in RPL10 R98S mutant T-ALL xenografted
patient samples (<xref ref-type="supplementary-material" rid="SD1">Figure
S3C</xref>, student’s t-test, p = 0.020), but not in isogenic Jurkat
T-ALL cells RPL10 R98S CRISPR-Cas9 cells (<xref ref-type="supplementary-material" rid="SD1">Figure S3D</xref>,
student’s t-test, p = 0.309). Elevated catalase expression was previously
described as a leukemic cell phenotype in patients, and might therefore not be
affected by RPL10 R98S in our Jurkat leukemic cell model.<xref ref-type="bibr" rid="R17">17</xref>,<xref ref-type="bibr" rid="R18">18</xref> These data
support that induced peroxisomal enzyme expression in RPL10 R98S mutant leukemia
cells may lead to higher peroxisomal β-oxidation activity.</p>
</sec>
<sec id="S18">
<title>RPL10 R98S cells accumulate ROS causing impaired cell proliferation</title>
<p id="P19">While the peroxisomal β-oxidation associated
H<sub>2</sub>O<sub>2</sub> production can be scavenged by catalase, system
overloading may lead to the accumulation of ROS (<xref ref-type="fig" rid="F1">Figure 1B</xref>).<xref ref-type="bibr" rid="R16">16</xref> Rpl10 R98S
mutant Ba/F3 cultures contained 25% more cells with high ROS levels (<xref ref-type="fig" rid="F1">Figure 1C</xref>/<xref ref-type="supplementary-material" rid="SD1">S4A</xref>, student’s
t-test, p = 0.018). Similarly, 20% more cells with high ROS levels were observed
in RPL10 R98S as compared to RPL10 WT Jurkat cultures (<xref ref-type="fig" rid="F1">Figure 1C</xref>/<xref ref-type="supplementary-material" rid="SD1">S4B</xref>, student’s t-test, p = 0.028), and 40% more cells with
high ROS occurred in Rpl10 R98S BM as compared to WT BM (<xref ref-type="fig" rid="F1">Figure 1C</xref>/<xref ref-type="supplementary-material" rid="SD1">S4C</xref>, student’s t-test, p = 0.022). To examine whether changes
in mitochondrial activity contributed to higher ROS percentages in R98S cells,
we explored <sup>13</sup>C<sub>6</sub>-Glucose tracing into metabolites of the
TCA cycle. Glucose tracer analysis<xref ref-type="bibr" rid="R19">19</xref>
demonstrated a decrease in the labeled carbons in M+4 to M+6 (mass distribution
vector) in citrate from <sup>13</sup>C<sub>6</sub>-Glucose and a concomitant
increase in M+2 labeling in Rpl10 R98S Ba/F3 and RPL10 R98S Jurkat cells in
comparison to WT cells (<xref ref-type="fig" rid="F2">Figure 2A</xref>,
student’s t-test, all p &lt; 0.05). This labeling pattern was
consistently observed in other TCA cycle metabolites and suggests decreased
oxidative phosphorylation in the TCA cycle (<xref ref-type="supplementary-material" rid="SD1">Figure S4D/E</xref>). In
addition, Rpl10 R98S Ba/F3 cells presented a 40% reduction in basal ATP levels
(<xref ref-type="supplementary-material" rid="SD1">Figure S4F</xref>,
student’s t-test, p &lt; 0.001). Lin- BM Rpl10 R98S colony forming
cell (CFC) cultures displayed a reduced percentage of cells with active
mitochondria (<xref ref-type="fig" rid="F2">Figure 2B</xref>, student’s
t-test, p = 0.001). Altogether, these observations support that RPL10 R98S is
associated with impaired mitochondrial function, and that elevated ROS levels
are thus likely to originate from the enhanced peroxisomal activity in RPL10
R98S cells. Oxidative stress driven by cellular H<sub>2</sub>O<sub>2</sub> ROS
accumulation has been shown to lead to mitochondrial dysfunction, such as
reduced mitochondrial respiration.<xref ref-type="bibr" rid="R21">21</xref>,<xref ref-type="bibr" rid="R22">22</xref> As oxidative stress has
previously been shown to perturb the proliferation of leukemia cells<xref ref-type="bibr" rid="R20">20</xref>, we explored neutralizing treatment with
the antioxidant N-acetylcysteine (Nac). Nac treatment completely abolished the
proliferation defect in Rpl10 R98S Ba/F3 cells (<xref ref-type="fig" rid="F2">Figure 2C</xref>). Collectively, these data demonstrate RPL10 R98S-specific
enhancement of peroxisomal β-oxidation, which leads to oxidative stress
through ROS accumulation, resulting in mitochondrial dysfunction and the
associated proliferation defect.</p>
</sec>
<sec id="S19">
<title>RPL10 R98S mutant cells possess an increased cell survival that is associated
with enhanced Bcl-2 expression</title>
<p id="P20">Under normal physiological conditions, cells encountering such high
levels of oxidative stress would undergo programmed cell death. WT cells treated
with H<sub>2</sub>O<sub>2</sub> show reduced cell viability due to enhanced
oxidative stress, while RPL10 R98S cells remained unaffected even upon further
increase of oxidative stress levels (<xref ref-type="supplementary-material" rid="SD1">Figure S5A</xref>). To investigate if RPL10 R98S cells have
adapted a general survival mechanism, we explored their cell survival capacity.
Ba/F3 Rpl10 R98S mutant cells displayed a clear survival benefit as compared to
RPL10 WT cells in overgrowth condition (cell culture having reached the growth
plateau, <xref ref-type="fig" rid="F3">Figure 3A</xref>, student’s
t-test, p &lt; 0.001), and independent of differences in residual nutrients
(<xref ref-type="fig" rid="F3">Figure 3B</xref>, student’s t-test, p
&lt; 0.001). RPL10 R98S mutation in T-ALL Jurkat cells caused
hypoproliferation, similar to our observation in Ba/F3 R98S cells (<xref ref-type="fig" rid="F3">Figure 3C</xref>, student’s t-test, p
&lt; 0.001).<xref ref-type="bibr" rid="R4">4</xref> Also RPL10 R98S Jurkat
cells presented an enhanced cell survival capacity in overgrowth condition,
supported by reduced levels of propidium iodide (PI) stained apoptotic cells
(<xref ref-type="fig" rid="F3">Figure 3D</xref>/<xref ref-type="supplementary-material" rid="SD1">S5B</xref>, student’s
t-test, p &lt; 0.001). Additionally, R98S Jurkat clones were more resistant
to apoptotic stimuli such as doxorubicin chemotherapy (<xref ref-type="supplementary-material" rid="SD1">Figure S5C</xref>). In line with
previous data, lin- Rpl10 R98S bone marrow cells displayed a reduced expansion
potential during the first replate (<xref ref-type="supplementary-material" rid="SD1">Figure S5D</xref>, Mann-Whitney U test, p = 0.043) in CFC assays.
However, RPL10 R98S cells presented an enhanced replating capacity at the
3<sup>rd</sup> and 4<sup>th</sup> re-plate, while Rpl10 WT replating
capacity was lost (<xref ref-type="fig" rid="F3">Figure 3E</xref>,
student’s t-test, for all p &lt; 0.05), supporting an enhanced
survival phenotype.</p>
<p id="P21">Proteome profiling showed an induction of anti-apoptotic Bcl-2
expression while other apoptosis regulators were unchanged or even decreased
(<xref ref-type="supplementary-material" rid="SD1">Figure S5E/F</xref>).
Immunoblot analysis confirmed increased BCL-2 expression in Rpl10 R98S Ba/F3
(<xref ref-type="fig" rid="F4">Figure 4A/B</xref>, student’s t-test,
p &lt; 0.001), RPL10 R98S CRISPR/Cas9 Jurkat cells (<xref ref-type="fig" rid="F4">Figure 4A/B</xref>, student’s t-test, p = 0.002), lin- BM
Rpl10 R98S cells (<xref ref-type="fig" rid="F4">Figure 4A/B</xref>,
student’s t-test, p &lt; 0.001), and in RPL10 R98S mutant patient
T-ALL xenografted samples (<xref ref-type="fig" rid="F4">Figure 4A/B</xref>,
student’s t-test, p &lt; 0.001). This BCL-2 upregulation was specific
to the ribosomal RPL10 R98S mutation, as mutations in RPL5 and RPL22 did not
enhance BCL-2 expression in Jurkat T-ALL cells (<xref ref-type="supplementary-material" rid="SD1">Figure S6</xref>).</p>
</sec>
<sec id="S20">
<title>RPL10 R98S cells display increased IRES-mediated Bcl-2 translation</title>
<p id="P22">BCL-2 is an important factor in the defense against oxidative
stress-induced apoptosis in leukemia cells.<xref ref-type="bibr" rid="R25">25</xref> While the <italic>Bcl-2</italic> mRNA levels were unchanged
between RPL10 WT and R98S Ba/F3 clones (<xref ref-type="supplementary-material" rid="SD1">Figure S7A</xref>), we observed a 1.6-fold enhanced ribosome
binding to <italic>Bcl-2</italic> mRNA (<xref ref-type="fig" rid="F5">Figure
5A</xref>, student’s t-test, p &lt; 0.001). Additionally, qRT-PCR
analysis on fractions collected from monosomes versus polysomes showed a shift
in <italic>Bcl-2</italic> mRNA distribution towards the heavy polysome fraction
in RPL10 R98S cells, supporting enhanced Bcl-2 translation efficiency by the
R98S mutant ribosome (<xref ref-type="supplementary-material" rid="SD1">Figure
S7B</xref>). BCL-2 protein translation can be cap-dependent or
IRES-mediated. BCL-2 has previously been shown to be regulated by stress-induced
IRES-mediated translation.<xref ref-type="bibr" rid="R26">26</xref> Alterations
in IRES-dependent BCL-2 translation was examined using specific dual luciferase
reporter assays (<xref ref-type="supplementary-material" rid="SD1">Figure
S7C</xref>). This revealed that RPL10 R98S Jurkat cells possess a 5-fold
increase in BCL-2 IRES translational activity as compared to WT cells (<xref ref-type="fig" rid="F5">Figure 5B</xref>, student’s t-test, p
&lt; 0.001). Upon cap-dependent translation inhibition, RPL10 R98S Jurkat
cells even showed a 9-fold increase in BCL-2 IRES translation (<xref ref-type="fig" rid="F5">Figure 5B</xref>, student’s t-test, p
&lt; 0.001). Involvement of oxidative stress in the regulation of BCL-2
translation was explored by Nac treatment. In line with previous data, Jurkat
leukemic RPL10 WT cells displayed reduced total and IRES-driven BCL-2
translation upon Nac treatment (<xref ref-type="fig" rid="F5">Figure 5C</xref>,
student’s t-test, p &lt; 0.001 for IRES and Cap-dependent
translation, p = 0.011 for IRES-driven translation).<xref ref-type="bibr" rid="R26">26</xref> However, the IRES-mediated BCL-2 reporter activity of
RPL10 R98S mutant Jurkat leukemia cells remained unchanged after Nac treatment
(<xref ref-type="fig" rid="F5">Figure 5C</xref>, student’s t-test, p
= 0.054 for IRES and Cap-dependent translation, p = 0.549 for IRES-driven
translation). These results emphasize that RPL10 R98S-mutant ribosomes have an
intrinsically higher preference for IRES-dependent BCL-2 translation, which is
likely to enhance their leukemic cell survival.</p>
</sec>
<sec id="S21">
<title>RPL10 R98S specific therapeutic targeting by BCL-2 inhibition</title>
<p id="P23">To investigate whether the elevated IRES-mediated BCL-2 translation in
RPL10 R98S leukemic cells provides a potential new selective therapeutic
opportunity, we tested the efficacy of the FDA approved clinical BCL-2 inhibitor
ABT-199 (venetoclax, RG7601, GDC-0199). Lin- BM Rpl10 R98S cells presented a
~50% reduction in CFC capacity in the presence of ABT-199, while Rpl10 WT
BM cells were not inhibited (<xref ref-type="fig" rid="F6">Figure 6A</xref>, p
&lt; 0.001). Jurkat RPL10 R98S cells were slightly more apoptotic upon
ABT-199 treatment as compared to RPL10 WT clones (<xref ref-type="supplementary-material" rid="SD1">Figure S8A</xref>). In
xenografted T-ALL samples, ABT-199 treatment induced apoptosis of RPL10 R98S
T-ALL cells, while no cellular responses were detected in RPL10 WT T-ALL cells
(<xref ref-type="supplementary-material" rid="SD1">Figure S8B</xref>). R98S
cells were not generally sensitized to targeting of anti-apoptotic proteins, as
RPL10 R98S lin- BM and Jurkat cells were less sensitive to MCL-1 inhibitor
maritoclax as compared to RPL10 WT cells (<xref ref-type="supplementary-material" rid="SD1">Figure S9A/B/C/D</xref>).
Moreover, RPL10 R98S cells could be re-sensitized to doxorubicin by the addition
of ABT-199 (<xref ref-type="supplementary-material" rid="SD1">Figure
S10</xref>). Combined, these findings highlight that BCL-2 driven enhanced
cellular resistance of RPL10 R98S cells can be efficiently targeted by ABT-199
treatment.</p>
<p id="P24">To further evaluate the effectiveness <italic>in vivo</italic>, RPL10 WT
and R98S pediatric T-ALL samples were injected into NSG mice (<xref ref-type="fig" rid="F6">Figure 6B</xref>), receiving DMSO or ABT-199 (50
mg/kg) therapy once a week when human CD45% in the peripheral blood (PB) reached
&gt;2%. The RPL10 WT X11 and X12 xenografted mice showed minimal sensitivity
to ABT-199 (n=5 DMSO versus n=5 ABT-199), and the percentages of human CD45
T-ALL cells in the PB of the mice were identical between DMSO and ABT-199
treated groups (<xref ref-type="fig" rid="F6">Figure 6C</xref>, p = 0.149 and p
= 0.428). The spleen weights were slightly reduced in the ABT-199 treated X11,
but not in X12 RPL10 WT xenografted mice (<xref ref-type="fig" rid="F6">Figure
6C</xref>, p = 0.040 and p = 0.603). The X12 animals all presented
&gt;95% human CD45 positive engraftment in BM (<xref ref-type="supplementary-material" rid="SD1">Figure S11A</xref>). In
contrast, the RPL10 R98S X13 and X15 xenografted mice treated with ABT-199 did
not show any signs of human CD45 leukemia progression in their PB, while
progressive disease was observed in DMSO treated animals (<xref ref-type="fig" rid="F6">Figure 6C</xref> and S11B/D, X13 n=5 DMSO and n=4 ABT-199 and X15
n=5 versus n=5). Splenomegaly caused by human leukemia progression in DMSO
treated animals was almost completely suppressed in ABT-199 treated animals
(<xref ref-type="fig" rid="F6">Figure 6C</xref>, X13 and X15 p &lt;
0.001), and the spleens of ABT-199 treated animals were only slightly larger
than the spleens from healthy NSG mice (<xref ref-type="fig" rid="F6">Figure
6C</xref>). Flow cytometry analysis revealed a 30-50% suppression of human
CD45 leukemia cell engraftment in the BM and the presence of 30-40% mouse CD45
cells in ABT-199 treated animals, whereas DMSO treated animals presented
&gt;95% human leukemia infiltration in the BM with a complete lack of mouse
CD45 expressing cells (<xref ref-type="supplementary-material" rid="SD1">Figure
S11C/E</xref>, X13 hCD45 and mCD45 both p &lt; 0.001, X15 hCD45 p =
0.009 and mCD45 p = 0.004). This was underscored by white femurs (lack of
erythropoiesis) in the DMSO treatment animals, while the femurs of ABT-199
treated animals remained red in color (<xref ref-type="supplementary-material" rid="SD1">Figure S11C</xref>). Altogether, these findings support that the
RPL10 R98S mutation induces IRES-driven BCL-2 translation that sensitizes RPL10
R98S pediatric T-ALL for BCL-2 targeted therapies such as
ABT-199/Venetoclax.</p>
</sec>
</sec>
<sec id="S22" sec-type="discussion">
<title>Discussion</title>
<p id="P25">In this study, we describe that RPL10 R98S leukemic cells harbor a
proliferative disadvantage due to enhanced cellular oxidative stress from the
accumulation of ROS (<xref ref-type="fig" rid="F7">Figure 7</xref>). Impairment of
mitochondria is a likely consequence of the oxidative stress, resulting in a robust
decrease in ATP levels and TCA cycle metabolites. It remains to be determined by
which mechanism RPL10 R98S cells upregulate peroxisomal activity causing
hypoproliferation. The proliferation impairment observed in different ribosomal
protein defective models has been linked to ribosome assembly defects.<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R27">27</xref>,<xref ref-type="bibr" rid="R28">28</xref> Such defects can be caused
by oxidative stress as well.<xref ref-type="bibr" rid="R29">29</xref> To our
knowledge, this is the first demonstration that a ribosomal mutation causes
hypoproliferation due to extensive oxidative stress and mitochondrial dysfunction.
This defect can be rescued by anti-oxidant treatment or possibly by acquired
secondary mutations.</p>
<p id="P26">While normal cells initiate programmed cell death upon
H<sub>2</sub>O<sub>2</sub> exposure, RPL10 R98S cells protect themselves via
enhanced IRES-dependent BCL-2 translation. The resulting constitutive BCL-2
expression facilitates and enhances leukemic RPL10 R98S cell survival (<xref ref-type="fig" rid="F7">Figure 7</xref>). The exact role of BCL-2 in the
observed phenotypes may be addressed in more detail by silencing and/or
overexpression of BCL-2 in RPL10 WT and R98S cells, and we cannot exclude that other
apoptosis regulators for which no protein expression data were available (such as
BAD, BMF, HRK, NOXA or PUMA) may also play a role. Nevertheless, we show that RPL10
R98S cells are highly sensitive to BCL-2 inhibitors, which have limited reactivity
to normal healthy cells and are in clinical usage for lymphoid malignancies.<xref ref-type="bibr" rid="R30">30</xref>–<xref ref-type="bibr" rid="R34">34</xref> Several research groups observed high expression of BCL-2 in early
T-cell precursor (ETP)-ALL and/or associations with JAK/STAT mutant cases, rendering
such samples sensitive to ABT-199.<xref ref-type="bibr" rid="R35">35</xref>–<xref ref-type="bibr" rid="R42">42</xref> However, the RPL10
R98S mutation mainly occurs in mature non-ETP-ALL.<xref ref-type="bibr" rid="R43">43</xref> The T-ALL sample X11 in our study harbored an activating JAK3
mutation (M511I). This sample did not show detectable BCL-2 protein expression, and
was not targeted by ABT-199 <italic>in vivo</italic> (<xref ref-type="fig" rid="F6">Figure 6C</xref>). We previously showed that RPL10 R98S enhances JAK/STAT
signaling.<xref ref-type="bibr" rid="R11">11</xref> Our current observations
support that RPL10 R98S regulates BCL-2 expression independently, preceding the
effects of RPL10 R98S on JAK/STAT pathway activation that only occurred during later
stages. The CRISPR-Cas9 engineered RPL10 R98S Jurkat cells show increased BCL-2
expression levels, while increased JAK/STAT pathway activation was not present.
Moreover, oxidative stress has been shown to modulate JAK/STAT pathway
regulation<xref ref-type="bibr" rid="R44">44</xref> and proteasome
complexes.<xref ref-type="bibr" rid="R45">45</xref> We could observe that JAK1
protein expression was slightly reduced upon Nac treatment in RPL10 R98S Ba/F3 cells
but not in RPL10 WT cells (<xref ref-type="supplementary-material" rid="SD1">Figure
S12</xref>), providing another mechanism for enhanced JAK/STAT pathway
activation in these cells.</p>
<p id="P27">The peroxisomal enzyme xanthine oxidase (XO) is involved in purine
degradation, with uric acid as a waste product.<xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R46">46</xref> Peroxisome-active RPL10
R98S leukemic cells may have contributed to the significantly higher uric acid
levels in the blood at diagnosis of RPL10 R98S mutant T-ALL patients as compared to
RPL10 WT T-ALL patients (RPL10 WT n=38 and RPL10 R98S n=15, <xref ref-type="supplementary-material" rid="SD1">Figure S13A</xref>, Mann Whitney-U
test, p = 0.041). In serum samples of RPL10 R98S T-ALL xenografted mice, we observed
a trend for increased uric acid levels upon leukemia development, which was
inhibited by ABT-199 treatment (<xref ref-type="supplementary-material" rid="SD1">Figure S12B</xref>). These observations suggest that uric acid levels at
diagnosis might be indicative for RPL10 R98S mutant T-ALL cases.</p>
<p id="P28">So far, only few examples of altered IRES-driven translation in disease have
been described. Changes in ribosomal RNA (rRNA) modifications can deregulate
translation rates of IRES-containing genes in cancer: IGF1R, MYC, FGF1, FGF2 and
VEGFA.<xref ref-type="bibr" rid="R47">47</xref> Moreover, hypo-pseudouridylation
of rRNA in the congenital disease dyskeratosis congenita reduces IRES-translation of
<italic>XIAP</italic>, <italic>TP53</italic>, <italic>CDKN1B</italic> and
<italic>BCL2L1</italic> and increases <italic>VEGF</italic> translation.<xref ref-type="bibr" rid="R48">48</xref>–<xref ref-type="bibr" rid="R50">50</xref> Inactivation of Diamond-Blackfan anemia genes <italic>RPS19</italic>
and <italic>RPL11</italic> impaired IRES–mediated translation of mRNAs
involved in erythroid development.<xref ref-type="bibr" rid="R51">51</xref> The
upregulation of IRES-dependent translation in RPL10 R98S cells seems to be specific
for the BCL-2 IRES, as other known cellular IRES-containing genes showed no
consistent increase in translation/expression in RPL10 R98S cells as revealed by
mass spectrometry (<xref ref-type="supplementary-material" rid="SD1">Table
S3</xref>).<xref ref-type="bibr" rid="R52">52</xref> The unique preference of
IRES-mediated translation specific to the RPL10 R98S mutation in leukemia provides a
novel mechanism for BCL-2 upregulation.</p>
</sec>
<sec id="SM" sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary information</label>
<media id="d36e949" mime-subtype="octet-stream" mimetype="application" orientation="portrait" position="anchor" xlink:href="NIHMS77878-supplement-Supplementary_information.docx" xlink:type="simple"></media>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S23">
<title>Acknowledgements</title>
<p>The authors would like to thank the patients who donated samples and the physician
assistants, nurse practitioners, and clinicians who acquired the samples. We thank
Prof. Adi Kimchi (Weizmann institute of science, Israel) for providing
dual-luciferase reporter plasmids.</p>
<p>K.R.K. was supported by the Lady Tata Memorial Trust International Award for research
in Leukaemia. S.O.S. is recipient of an EMBO long-term postdoctoral fellowship and
the EHA José Carreras Junior Research Grant. T.G. was supported by a
fellowship “Emmanuel van der Schueren” from Kom op tegen Kanker. B.V.
and S.V. are SB PhD fellow at FWO (n° 1S07118N and 1S49817N). G.R. is
supported by consecutive PhD fellowships from the Emmanuel van der Schueren - Kom op
tegen Kanker foundation and FWO. S.M.F. acknowledges funding support from the
Concern Foundation (Conquer Cancer Now) and KU-Leuven Methusalem Co-funding. P.V.
and D.C. have senior clinical investigator fellowships of the FWO Vlaanderen. This
research was funded by an ERC starting grant (n°334946), FWO funding
(G084013N and 1509814N) and a Stichting Tegen Kanker grant (grant n° 2012-176
and 2016-775) to K.D.K and by the leukemia research grant 2017 from the “Me
To You" foundation to K.R.K.</p>
</ack>
<fn-group>
<fn fn-type="COI-statement" id="FN1">
<p id="P29"><bold>The authors declare no potential conflicts of interest</bold>.</p>
</fn>
<fn fn-type="con" id="FN2">
<p id="P30">
<bold>Authorship contribution</bold>
</p>
<p id="P31">K.R.K designed research, performed research, collected data, analyzed
data and wrote the paper. S.O.S conducted the BCL2 IRES-reporter assays and
wrote and edited the manuscript. B.V. and S.V. generated the CRISPR-Cas9 Jurkat
clones. T.G. and J.O.d.B. generated Ba/F3 clones containing human RPL10 WT or
R98S, G.R and S.F. performed and interpreted the
<sup>13</sup>C<sub>6</sub>-Glucose tracing experiment. J.V. facilitated the mice
studies, and P.S. performed ATP analysis. A.U., A.V.M., C.J.H., J.P.P.M., and
J.C. provided the pediatric T-ALL patient data and samples. P.V. and D.C.
measured uric acid levels in serum samples. K.D.K designed research, supervised
the study and wrote the paper.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girardi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Vicente</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cools</surname>
<given-names>J</given-names>
</name>
<name>
<surname>De Keersmaecker</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>The genetics and molecular biology of T-ALL</article-title>
<source/>Blood
          <year>2017</year>
<volume>129</volume>
<fpage>1113</fpage>
<lpage>1123</lpage>
<pub-id pub-id-type="pmid">28115373</pub-id>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooper</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>PA</given-names>
</name>
</person-group>
<article-title>Treatment of pediatric acute lymphoblastic
leukemia</article-title>
<source/>Pediatr Clin North Am
          <year>2015</year>
<volume>62</volume>
<fpage>61</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="pmid">25435112</pub-id>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Gutierrez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Perrigoue</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Thapa</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Tu</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inactivation of ribosomal protein L22 promotes transformation by
induction of the stemness factor, Lin28B</article-title>
<source/>Blood
          <year>2012</year>
<volume>120</volume>
<fpage>3764</fpage>
<lpage>3773</lpage>
<pub-id pub-id-type="pmid">22976955</pub-id>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Keersmaecker</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Atak</surname>
<given-names>ZK</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Vicente</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Patchett</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Girardi</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exome sequencing identifies mutation in CNOT3 and ribosomal genes
RPL5 and RPL10 in T-cell acute lymphoblastic leukemia</article-title>
<source/>Nat Genet
          <year>2013</year>
<volume>45</volume>
<fpage>186</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">23263491</pub-id>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tzoneva</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Perez-Garcia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Carpenter</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Khiabanian</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tosello</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Allegretta</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activating mutations in the NT5C2 nucleotidase gene drive
chemotherapy resistance in relapsed ALL</article-title>
<source/>Nat Med
          <year>2013</year>
<volume>19</volume>
<fpage>368</fpage>
<lpage>371</lpage>
<pub-id pub-id-type="pmid">23377281</pub-id>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sulima</surname>
<given-names>SO</given-names>
</name>
<name>
<surname>Patchett</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Advani</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>De Keersmaecker</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Dinman</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Bypass of the pre-60S ribosomal quality control as a pathway to
oncogenesis</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2014</year>
<volume>111</volume>
<fpage>5640</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">24706786</pub-id>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inada</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mukai</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Matsushima</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>QM is a novel zinc-binding transcription regulatory protein: its
binding to c-Jun is regulated by zinc ions and phosphorylation by protein
kinase C</article-title>
<source/>Biochem Biophys Res Commun
          <year>1997</year>
<volume>230</volume>
<fpage>331</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">9016777</pub-id>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monteclaro</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Vogt</surname>
<given-names>PK</given-names>
</name>
</person-group>
<article-title>A Jun-binding protein related to a putative tumor
suppressor</article-title>
<source/>Proc Natl Acad Sci
          <year>1993</year>
<volume>90</volume>
<fpage>6726</fpage>
<lpage>6730</lpage>
<pub-id pub-id-type="pmid">8341691</pub-id>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oh</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>CH</given-names>
</name>
</person-group>
<article-title>QM, a putative tumor suppressor, regulates proto-oncogene
c-Yes</article-title>
<source/>J Biol Chem
          <year>2002</year>
<volume>277</volume>
<fpage>36489</fpage>
<lpage>36498</lpage>
<pub-id pub-id-type="pmid">12138090</pub-id>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiocchetti</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Haslinger</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Boesch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Karl</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wiemann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Freitag</surname>
<given-names>CM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Protein signatures of oxidative stress response in a patient
specific cell line model for autism</article-title>
<source/>Mol Autism
          <year>2014</year>
<volume>5</volume>
<fpage>10</fpage>
<pub-id pub-id-type="pmid">24512814</pub-id>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girardi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Vereecke</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sulima</surname>
<given-names>SO</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fancello</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Briggs</surname>
<given-names>JW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The T-cell leukemia associated ribosomal RPL10 R98S mutation
enhances JAK-STAT signaling</article-title>
<source/>Leukemia
          <year>2017</year>
<volume>32</volume>
<fpage>809</fpage>
<lpage>819</lpage>
<pub-id pub-id-type="pmid">28744013</pub-id>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elia</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Broekaert</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Christen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Boon</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Radaelli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Orth</surname>
<given-names>MF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Proline metabolism supports metastasis formation and could be
inhibited to selectively target metastasizing cancer cells</article-title>
<source/>Nat Commun
          <year>2017</year>
<volume>8</volume>
<fpage>15267</fpage>
<pub-id pub-id-type="pmid">28492237</pub-id>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lorendeau</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schmieder</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Broekaert</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Metzger</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Veys</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Breast Cancer-Derived Lung Metastases Show Increased Pyruvate
Carboxylase-Dependent Anaplerosis</article-title>
<source/>Cell Rep
          <year>2016</year>
<volume>17</volume>
<fpage>837</fpage>
<lpage>848</lpage>
<pub-id pub-id-type="pmid">27732858</pub-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lorendeau</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rinaldi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Boon</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Spincemaille</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Metzger</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jäger</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dual loss of succinate dehydrogenase (SDH) and complex I activity
is necessary to recapitulate the metabolic phenotype of SDH mutant
tumors</article-title>
<source/>Metab Eng
          <year>2016</year>
<volume>43</volume>
<issue>Pt B</issue>
<fpage>187</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="pmid">27847310</pub-id>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marash</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liberman</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Henis-Korenblit</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sivan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Reem</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Elroy-Stein</surname>
<given-names>O</given-names>
</name>
<etal></etal>
</person-group>
<article-title>DAP5 Promotes Cap-Independent Translation of Bcl-2 and CDK1 to
Facilitate Cell Survival during Mitosis</article-title>
<source/>Mol Cell
          <year>2008</year>
<volume>30</volume>
<fpage>447</fpage>
<lpage>459</lpage>
<pub-id pub-id-type="pmid">18450493</pub-id>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fransen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nordgren</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Apanasets</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Role of peroxisomes in ROS/RNS-metabolism: Implications for human
disease</article-title>
<source/>Biochim Biophys Acta - Mol Basis Dis
          <year>2012</year>
<volume>1822</volume>
<fpage>1363</fpage>
<lpage>1373</lpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>López-Pedrera</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Villalba</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Siendones</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Barbarroja</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gómez-Díaz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rodríguez-Ariza</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Proteomic analysis of acute myeloid leukemia: Identification of
potential early biomarkers and therapeutic targets</article-title>
<source/>Proteomics
          <year>2006</year>
<volume>6</volume>
<fpage>S293</fpage>
<lpage>S299</lpage>
<pub-id pub-id-type="pmid">16521150</pub-id>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zelen</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Djurdjevic</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Popovic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stojanovic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jakovljevic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Radivojevic</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antioxidant enzymes activities and plasma levels of oxidative
stress markers in B-chronic lymphocytic leukemia patients</article-title>
<source/>J BUON
          <year>2010</year>
<volume>15</volume>
<fpage>330</fpage>
<lpage>336</lpage>
<pub-id pub-id-type="pmid">20658731</pub-id>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buescher</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Antoniewicz</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Boros</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Burgess</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Brunengraber</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Clish</surname>
<given-names>CB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A roadmap for interpreting 13C metabolite labeling patterns from
cells</article-title>
<source/>Curr Opin Biotechnol
          <year>2015</year>
<volume>34</volume>
<fpage>189</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="pmid">25731751</pub-id>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kulkarni</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Mittal</surname>
<given-names>SPK</given-names>
</name>
<name>
<surname>Devasagayam</surname>
<given-names>TPa</given-names>
</name>
<name>
<surname>Pal</surname>
<given-names>JK</given-names>
</name>
</person-group>
<article-title>Oxidative stress perturbs cell proliferation in human K562 cells
by modulating protein synthesis and cell cycle</article-title>
<source/>Free Radic Res
          <year>2009</year>
<volume>43</volume>
<fpage>1090</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="pmid">19669995</pub-id>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Oxidative stress, mitochondrial damage and neurodegenerative
diseases</article-title>
<source/>Neural Regen Res
          <year>2013</year>
<volume>8</volume>
<fpage>2003</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">25206509</pub-id>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nulton-Persson</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Szweda</surname>
<given-names>LI</given-names>
</name>
</person-group>
<article-title>Modulation of mitochondrial function by hydrogen
peroxide</article-title>
<source/>J Biol Chem
          <year>2001</year>
<volume>276</volume>
<fpage>23357</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">11283020</pub-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Battisti</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Maders</surname>
<given-names>LDK</given-names>
</name>
<name>
<surname>Bagatini</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Spanevello</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Maldonado</surname>
<given-names>Pa</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Measurement of oxidative stress and antioxidant status in acute
lymphoblastic leukemia patients</article-title>
<source/>Clin Biochem
          <year>2008</year>
<volume>41</volume>
<fpage>511</fpage>
<lpage>518</lpage>
<pub-id pub-id-type="pmid">18313403</pub-id>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sallmyr</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rassool</surname>
<given-names>FV</given-names>
</name>
</person-group>
<article-title>Genomic instability in myeloid malignancies: Increased reactive
oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone
repair</article-title>
<source/>Cancer Lett
          <year>2008</year>
<volume>270</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">18467025</pub-id>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Sohn</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Son</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Tockgo</surname>
<given-names>YC</given-names>
</name>
</person-group>
<article-title>Regulation of bcl-2 family in hydrogen peroxide-induced apoptosis
in human leukemia HL-60 cells</article-title>
<source/>Exp Mol Med
          <year>2000</year>
<volume>32</volume>
<fpage>42</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="pmid">10762061</pub-id>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sherrill</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Byrd</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Van Eden</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Lloyd</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>BCL-2 translation is mediated via internal ribosome entry during
cell stress</article-title>
<source/>J Biol Chem
          <year>2004</year>
<volume>279</volume>
<fpage>29066</fpage>
<lpage>29074</lpage>
<pub-id pub-id-type="pmid">15123638</pub-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirn-Safran</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Oristian</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Focht</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Vivian</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Carson</surname>
<given-names>DD</given-names>
</name>
</person-group>
<article-title>Global growth deficiencies in mice lacking the ribosomal protein
HIP/RPL29</article-title>
<source/>Dev Dyn
          <year>2007</year>
<volume>236</volume>
<fpage>447</fpage>
<lpage>460</lpage>
<pub-id pub-id-type="pmid">17195189</pub-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teng</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mercer</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Hexley</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fumagalli</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Loss of Tumor Suppressor RPL5/RPL11 Does Not Induce Cell Cycle
Arrest but Impedes Proliferation Due to Reduced Ribosome Content and
Translation Capacity</article-title>
<source/>Mol Cell Biol
          <year>2013</year>
<volume>33</volume>
<fpage>4660</fpage>
<lpage>4671</lpage>
<pub-id pub-id-type="pmid">24061479</pub-id>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shenton</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Smirnova</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Selley</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hubbard</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Pavitt</surname>
<given-names>GD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Global translational responses to oxidative stress impact upon
multiple levels of protein synthesis</article-title>
<source/>J Biol Chem
          <year>2006</year>
<volume>281</volume>
<fpage>29011</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="pmid">16849329</pub-id>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Iragavarapu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Savooji</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>ABT-199 (venetoclax) and BCL-2 inhibitors in clinical
development</article-title>
<source/>J Hematol Oncol
          <year>2015</year>
<volume>8</volume>
<fpage>129</fpage>
<pub-id pub-id-type="pmid">26589495</pub-id>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerecitano</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Seymour</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Wierda</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Kahl</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Pagel</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in
Patients with Relapsed/Refractory Non-Hodgkin Lymphoma</article-title>
<source/>Blood
          <year>2015</year>
<volume>126</volume>
<fpage>254</fpage>
<lpage>254</lpage>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seymour</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Gerecitano</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Kahl</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Pagel</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Wierda</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>M-A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients
With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses
Observed In All Mantle Cell Lymphoma (MCL) Patients</article-title>
<source/>Blood
          <year>2013</year>
<volume>122</volume>
<fpage>1789</fpage>
<lpage>1789</lpage>
<pub-id pub-id-type="pmid">23869085</pub-id>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roberts</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Davids</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Pagel</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Kahl</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Puvvada</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Gerecitano</surname>
<given-names>JF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic
Leukemia</article-title>
<source/>N Engl J Med
          <year>2016</year>
<volume>374</volume>
<fpage>311</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="pmid">26639348</pub-id>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stilgenbauer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Eichhorst</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schetelig</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Coutre</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Seymour</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Munir</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Venetoclax in relapsed or refractory chronic lymphocytic
leukaemia with 17p deletion: a multicentre, open-label, phase 2
study</article-title>
<source/>Lancet Oncol
          <year>2016</year>
<volume>17</volume>
<fpage>768</fpage>
<lpage>778</lpage>
<pub-id pub-id-type="pmid">27178240</pub-id>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ni Chonghaile</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Roderick</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Glenfield</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sallan</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Silverman</surname>
<given-names>LB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Maturation stage of T-cell acute lymphoblastic leukemia
determines BCL-2 versus BCL-XL dependence and sensitivity to
ABT-199</article-title>
<source/>Cancer Discov
          <year>2014</year>
<volume>4</volume>
<fpage>1074</fpage>
<lpage>1087</lpage>
<pub-id pub-id-type="pmid">24994123</pub-id>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maude</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Dolai</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Delgado-martin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Robbins</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Selvanathan</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Efficacy of JAK / STAT pathway inhibition in murine xenograft
models of early T-cell precursor (ETP) acute lymphoblastic
leukemia</article-title>
<source/>Blood
          <year>2015</year>
<volume>125</volume>
<fpage>1759</fpage>
<lpage>1768</lpage>
<pub-id pub-id-type="pmid">25645356</pub-id>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peirs</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Matthijssens</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Goossens</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Van I de</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ruggero</surname>
<given-names>K</given-names>
</name>
<name>
<surname>de Bock</surname>
<given-names>CE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ABT-199 mediated inhibition of BCL-2 as a novel therapeutic
strategy in T-cell acute lymphoblastic leukemia</article-title>
<source/>Blood
          <year>2014</year>
<volume>124</volume>
<fpage>3738</fpage>
<lpage>3747</lpage>
<pub-id pub-id-type="pmid">25301704</pub-id>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frismantas</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Dobay</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Rinaldi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tchinda</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Kunz</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ex vivo drug response pro fi ling detects recurrent sensitivity
patterns in drug-resistant acute lymphoblastic leukemia</article-title>
<source/>e- Blood
          <year>2017</year>
<volume>129</volume>
<fpage>26</fpage>
<lpage>38</lpage>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peirs</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Frismantas</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Matthijssens</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Van Loocke</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Pieters</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Vandamme</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Targeting BET proteins improves the therapeutic efficacy of BCL-2
inhibition in T-cell acute lymphoblastic leukemia</article-title>
<source/>Leukemia
          <year>2017</year>
<volume>31</volume>
<fpage>2037</fpage>
<lpage>2047</lpage>
<pub-id pub-id-type="pmid">28074072</pub-id>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Holmfeldt</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Heatley</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Payne-Turner</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The genetic basis of early T-cell precursor acute lymphoblastic
leukaemia</article-title>
<source/>Nature
          <year>2012</year>
<volume>481</volume>
<fpage>157</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">22237106</pub-id>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Miskimen</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>XY</given-names>
</name>
<name>
<surname>Brenzovich</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>JJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>STAT5 requires the N-domain for suppression of miR15/16,
induction of bcl-2, and survival signaling in myeloproliferative
disease</article-title>
<source/>Blood
          <year>2010</year>
<volume>115</volume>
<fpage>1416</fpage>
<lpage>1424</lpage>
<pub-id pub-id-type="pmid">20008792</pub-id>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waibel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Solomon</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Ralli</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Banks</surname>
<given-names>KM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant
JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2
Inhibitors</article-title>
<source/>Cell Rep
          <year>2013</year>
<volume>5</volume>
<fpage>1047</fpage>
<lpage>1059</lpage>
<pub-id pub-id-type="pmid">24268771</pub-id>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Easton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Maciaszek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>MR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The genomic landscape of pediatric and young adult T-lineage
acute lymphoblastic leukemia</article-title>
<source/>Nat Genet
          <year>2017</year>
<volume>49</volume>
<fpage>1211</fpage>
<lpage>1218</lpage>
<pub-id pub-id-type="pmid">28671688</pub-id>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simon</surname>
<given-names>aR</given-names>
</name>
<name>
<surname>Rai</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Fanburg</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Cochran</surname>
<given-names>BH</given-names>
</name>
</person-group>
<article-title>Activation of the JAK-STAT pathway by reactive oxygen
species</article-title>
<source/>Am J Physiol
          <year>1998</year>
<volume>275</volume>
<fpage>C1640</fpage>
<lpage>C1652</lpage>
<pub-id pub-id-type="pmid">9843726</pub-id>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aiken</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Kaake</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Stumpf</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Mishto</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative Stress-Mediated Regulation of Proteasome
Complexes</article-title>
<source/>Mol Cell Proteomics
          <year>2011</year>
<volume>10</volume>
<comment>R110.006924-R110.006924</comment>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maiuolo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Oppedisano</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gratteri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Muscoli</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mollace</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Regulation of uric acid metabolism and excretion</article-title>
<source/>Int J Cardiol
          <year>2016</year>
<volume>213</volume>
<fpage>8</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">26316329</pub-id>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marcel</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ghayad</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Belin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Therizols</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Morel</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Solano-Gonzàlez</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>P53 Acts as a Safeguard of Translational Control by Regulating
Fibrillarin and rRNA Methylation in Cancer</article-title>
<source/>Cancer Cell
          <year>2013</year>
<volume>24</volume>
<fpage>318</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="pmid">24029231</pub-id>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Brandenburger</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zollo</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Rego</surname>
<given-names>E</given-names>
</name>
<name>
<surname>R</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Impaired Control of IRES-Mediated Translation in X-Linked
Dyskeratosis Congenita</article-title>
<source/>Science (80- )
          <year>2006</year>
<volume>312</volume>
<fpage>902</fpage>
<lpage>906</lpage>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montanaro</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Calienni</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bertoni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rocchi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sansone</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Storci</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Novel dyskerin-mediated mechanism of p53 inactivation through
defective mRNA translation</article-title>
<source/>Cancer Res
          <year>2010</year>
<volume>70</volume>
<fpage>4767</fpage>
<lpage>4777</lpage>
<pub-id pub-id-type="pmid">20501855</pub-id>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rocchi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pacilli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sethi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Penzo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Treré</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dyskerin depletion increases VEGF mRNA internal ribosome entry
site-mediated translation</article-title>
<source/>Nucleic Acids Res
          <year>2013</year>
<volume>41</volume>
<fpage>8308</fpage>
<lpage>8318</lpage>
<pub-id pub-id-type="pmid">23821664</pub-id>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horos</surname>
<given-names>R</given-names>
</name>
<name>
<surname>IJspeert</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Pospisilova</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sendtner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Andrieu-Soler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Taskesen</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ribosomal deficiencies in Diamond-Blackfan anemia impair
translation of transcripts essential for differentiation of murine and human
erythroblasts</article-title>
<source/>Blood
          <year>2012</year>
<volume>119</volume>
<fpage>262</fpage>
<lpage>272</lpage>
<pub-id pub-id-type="pmid">22058113</pub-id>
</element-citation>
</ref>
<ref id="R52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mokrejs</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>IRESite: the database of experimentally verified IRES structures
(<ext-link ext-link-type="uri" xlink:href="http://www.iresite.org/">www.iresite.org</ext-link>)</article-title>
<source/>Nucleic Acids Res
          <year>2006</year>
<volume>34</volume>
<fpage>D125</fpage>
<lpage>D130</lpage>
<pub-id pub-id-type="pmid">16381829</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<title>RPL10 R98S enhances peroxisomal activity and is associated with oxidative
stress.</title>
<p>(A) Heatmap representing significantly (p &lt; 0.01) upregulated peroxisome
proteins in RPL10 WT and R98S Ba/F3 clones. Values are normalized spectral
counts as determined using the Scaffold analysis software. (B) Overview of the
peroxisome dysregulation in RPL10 R98S mutant cells. (C) Flow cytometry analysis
of ROS levels showing the percentage DHE expressing cells from the total
population in different RPL10 R98S cell models: (left) Ba/F3 lymphoid cells,
(middle) Jurkat T-ALL cells, (right) lin- BM CFC assay cells. Box-plots show the
data median and error bars define data distribution.</p>
</caption>
<graphic xlink:href="emss-77878-f001"></graphic>
</fig>
<fig id="F2" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<title>Mitochondrial dysfunction and the associated proliferation defect in RPL10
R98S cells can be restored by neutralizing oxidative stress.</title>
<p>(A) Metabolic tracing analysis (<sup>13</sup>C<sub>6</sub>-Glucose) measuring the
mass distribution vector presented as % citrate derived from labeled glucose.
Left: comparison of three independent Ba/F3 RPL10 WT clones versus three RPL10
R98S clones. Right: technical triplicates for RPL10 WT Jurkat and RPL10 R98S
mutant Jurkat cells. Data are represented as mean ± SD. (B) Mitotracker
flow cytometry analysis of Rpl10 WT and R98S CFC assay cells. Three independent
CFC plates per BM donor were analyzed. Box-plots show the median and error bars
define data distribution. (C) MTS cell proliferation assay analysis of Ba/F3
RPL10 WT and R98S clones either untreated or treated with 5mM Nac (optical
densitometry). Data are represented as mean ± SD. Statistical analysis *
p-value &lt; 0.05, ** p-value &lt; 0.01, *** p-value &lt; 0.001. #
clone ID and donor mouse ID.</p>
</caption>
<graphic xlink:href="emss-77878-f002"></graphic>
</fig>
<fig id="F3" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<title>The RPL10 R98S mutation promotes a survival benefit.</title>
<p>(A) Viable cell counts (day 5) of Ba/F3 RPL10 WT clones versus R98S clones
(overgrowth condition, triplicate measurement). (B) Ba/F3 RPL10 WT and R98S
clones were grown at 2*10^6 for two days in exhausted media derived from
overgrown Ba/F3 parental cells (viable cell counts). (C) Proliferation curve of
RPL10 WT and RPL10 R98S Jurkat clones during 72h of culturing (cell counts in
quadruplicate/24h). (D) Percentage of viable cells at day 5 of culture
(overgrowth condition, triplicate measurement). (E) CFC assay using Rpl10 WT or
Rpl10 R98S mouse lin- BM (CFC in duplicate/mice). Data are represented as mean
± SD. Statistical analysis * p-value &lt; 0.05, *** p-value &lt;
0.001. # clone ID and donor mouse ID.</p>
</caption>
<graphic xlink:href="emss-77878-f003"></graphic>
</fig>
<fig id="F4" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<title>RPL10 R98S mutant cells present enhanced BCL-2 protein expression.</title>
<p>(A) Immunoblot analysis of BCL-2 in several RPL10 WT and RPL10 R98S mutant cell
models. (B) Quantification of immunoblot analysis. Box-plots represent the
median and error bars define data distribution for RPL10 WT (grey) and RPL10
R98S mutant (blue) cases. Statistical analysis ** p-value &lt; 0.01, ***
p-value &lt; 0.001. # clone ID and donor mouse ID.</p>
</caption>
<graphic xlink:href="emss-77878-f004"></graphic>
</fig>
<fig id="F5" orientation="portrait" position="float">
<label>Figure 5</label>
<caption>
<title>RPL10 R98S cells display elevated BCL-2 IRES-mediated translation.</title>
<p>(A) Overall ribosome bound <italic>Bcl-2</italic> mRNA levels relative to Hprt
mRNA binding. Box-plots represent the median and error bars define data
distribution for the overall <italic>Bcl-2/Hprt</italic> ratio in sucrose
gradient fractions. (B/C) BCL-2 IRES reporter assay read outs of RPL10 WT and
R98S clones. Data are represented as mean ± SD. (B) On the left, the
overall IRES and Cap-dependent BCL-2 translation and on the right IRES-driven
BCL-2 translation. (C) In the presence or absence of Nac anti-oxidant treatment.
RPL10 WT (grey) and RPL10 R98S (blue). Statistical analysis * p-value &lt;
0.05, ** p-value &lt; 0.01, *** p-value &lt; 0.001. WT and R98S numbers
represent the different Jurkat clone ID’s.</p>
</caption>
<graphic xlink:href="emss-77878-f005"></graphic>
</fig>
<fig id="F6" orientation="portrait" position="float">
<label>Figure 6</label>
<caption>
<title>RPL10 R98S cells show selective sensitivity to BCL-2 inhibition <italic>in
vitro</italic> and <italic>in vivo</italic>.</title>
<p>(A) CFC assay of Rpl10 WT or Rpl10 R98S knock in mouse lin- BM cells in the
absence or presence of the Bcl-2 inhibitor venetoclax (ABT-199, 1 μM, in
triplicate for two individual RPL10 WT and R98S donor mice). The box-plots
present the median viable cell count and error bars define data distribution.
(B) Experimental <italic>in vivo</italic> study design for xenografting T-ALL
patient samples in NSG mice. (C) On the left flow cytometry analysis of human
CD45 cells in the blood of the animals and on the right the associated spleen
weights of mice injected with RPL10 WT X11 and X12 and RPL10 R98S X13 and X15
T-ALL that progressed to the leukemia disease end stage, comparing DMSO and
ABT-199 treated animals to healthy control animals. Data are presented as
individual data points. Statistical analysis * p-value &lt; 0.05, ***
p-value &lt; 0.001.</p>
</caption>
<graphic xlink:href="emss-77878-f006"></graphic>
</fig>
<fig id="F7" orientation="portrait" position="float">
<label>Figure 7</label>
<caption>
<title>Schematic model representing the leukemic RPL10 R98S mechanism.</title>
<p>Two phenotypes can be observed; 1) enhanced peroxisomal function generating ROS,
which causes a proliferation defect, and 2) a mutant ribosomal preference for
BCL-2 IRES-mediated translation. Enhanced BCL-2 can be efficiently targeted by
ABT-199/venetoclax treatment.</p>
</caption>
<graphic xlink:href="emss-77878-f007"></graphic>
</fig>
</floats-group>
</article>
</pmc-articleset>